Korea Pfizer (CEO O Dong-wook) announced that, following a Ministry of Health and Welfare notice, its TNF inhibitor Enbrel (etanercept) will be covered by the national health insurance for patients with severe active non‑radiographic axial spondyloarthritis (nr‑axSpA) starting September 1.
Non‑radiographic axial spondyloarthritis is a type of axial spondyloarthritis where X‑ray imaging does not show clear structural damage of the sacroiliac joints, but patients still experience significant pain and disease burden.
規制動向2026年9月15日•3分で読めます
Korea Pfizer’s Enbrel Gains Health Insurance Coverage for nr-axSpA
Korea Pfizer announced that etanercept (Enbrel) will be reimbursed by national health insurance for severe active non‑radiographic axial spondyloarthritis patients starting September 1, expanding treatment access.
Pharmacountryチームがまとめました · 出典： KPA News
トピック：
評価
(0)
(0)
(0)
(0)
(0)
評価を残す